Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) posted its quarterly earnings results on Thursday. The company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14, Zacks reports. The firm had revenue of $846.23 million during the quarter, compared to analysts’ expectations of $879.40 million. Swedish Orphan Biovitrum had a positive return on equity of 13.66% and a negative net margin of 0.97%.

Swedish Orphan Biovitrum Stock Performance

BIOVF stock remained flat at $37.00 during trading on Friday. 1 shares of the company traded hands, compared to its average volume of 1. The stock has a market cap of $13.17 billion, a PE ratio of -528.57 and a beta of 0.37. Swedish Orphan Biovitrum has a 12-month low of $25.80 and a 12-month high of $37.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.69 and a current ratio of 1.02. The stock has a 50 day moving average of $35.96 and a 200 day moving average of $33.07.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft upgraded shares of Swedish Orphan Biovitrum from a “sell” rating to a “buy” rating in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.